en · de · es · fr · pt
faq-desk.peptides6579.com › Wiki › Background And Development History — Complete Guide

Background And Development History — Complete Guide

By Editorial Desk · published 2026-06-14 · last reviewed 2026-08-01 · Wiki

nasal drops is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Development History

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

Semax 的储存、稳定性与分析

常规纯度与身份确认依赖反相高效液相色谱,并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成,肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同,因此各实验室报告的纯度数值不宜直接横向比较。

多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下,同时避免光照与反复升温。短期运输有时采用冷藏条件,但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数,以降低吸湿和微生物污染的风险。开封后若未一次用完,建议在干燥环境中密封并尽快放回低温储存。

溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集,其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸,因此氧化风险相对突出。工作液一般主张现配现用,或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率,而关于最佳条件的公开数据并不统一。

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalogue of the ACTH(4-10) fragment
Amino acid sequenceMet-Glu-His-Phe-Pro-Gly-ProSingle-letter form MEHFPGP
Molecular formulaC37H51N9O10SFree peptide, nominal mass near 814 Da
First registration1994, RussiaNasal formulation for neurological indications
Typical purity grade95% or higher by HPLCResearch material; higher grades used as reference standards

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Related pages on this site

Handling, Stability, and Quality Control

Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.

Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.

Semax Peptide Structure and Origin

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

Reference notes

=== Chemical === Flerovium is the heaviest known member of group 14, below lead, and is projected to be the second member of the 7p series of elements. Nihonium and flerovium are expected to form a very short subperiod corresponding to the filling of the 7p1/2 orbital, coming between the filling of the 6d5/2 and 7p3/2 subshells. Their chemical behaviour is expected to be very distinctive: nihonium's homology to thallium has been called "doubtful" by computational chemists, while flerovium's to lead has been called only "formal". The first five group 14 members show a +4 oxidation state and the latter members have increasingly prominent +2 chemistry due to onset of the inert pair effect. For tin, the +2 and +4 states are similar in stability, and lead(II) is the most stable of all the chemically well-understood +2 oxidation states in group 14. The 7s orbitals are very highly stabilized in flerovium, so a very large sp3 orbital hybridization is needed to achieve a +4 oxidation state, so flerovium is expected to be even more stable than lead in its strongly predominant +2 oxidation state and its +4 oxidation state should be highly unstable.

Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). Naturally occurring AGIs are found in raw plants/herbs such as cinnamon and white mulberry as well as some bacteria. Carbohydrates are normally converted into simple sugars (monosaccharides) by alpha-glucosidase enzymes present on cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar.

==== Amino acid substitution models ==== For many analyses, particularly for longer evolutionary distances, the evolution is modeled on the amino acid level. Since not all DNA substitution also alter the encoded amino acid, information is lost when looking at amino acids instead of nucleotide bases. However, several advantages speak in favor of using the amino acid information: DNA is much more inclined to show compositional bias than amino acids, not all positions in the DNA evolve at the same speed (non-synonymous mutations are less likely to become fixed in the population than synonymous ones), but probably most important, because of those fast evolving positions and the limited alphabet size (only four possible states), the DNA suffers from more back substitutions, making it difficult to accurately estimate evolutionary longer distances. Unlike the DNA models, amino acid models traditionally are empirical models. They were pioneered in the 1960s and 1970s by Dayhoff and co-workers by estimating replacement rates from protein alignments with at least 85% identity (originally with very limited data and ultimately culminating in the Dayhoff PAM model of 1978). This minimized the chances of observing multiple substitutions at a site. From the estimated rate matrix, a series of replacement probability matrices were derived, known under names such as PAM250.

In the simulated moving bed technique instead of moving the bed, the feed inlet, the solvent or eluent inlet and the desired product exit and undesired product exit positions are moved continuously, giving the impression of a moving bed, with continuous flow of solid particles and continuous flow of liquid in the opposite direction of the solid particles.

==== Alternative binding mechanisms ==== The LFT principle works with any collection of molecules that bind to each other with high affinity, so long as some of them can be immobilized to the gold nanoparticles and the test line respectively. For example:

Sources: en.wikipedia.org

Notes from published material

A 2018 meta-analysis found no higher risk of breast cancer with 5α-reductase inhibitors. Sexual and mood side effects, such as erectile dysfunction, loss of libido, depression, and reduced semen volume occur in as many as 4.8% of patients taking 5α-reductase inhibitors including dutasteride. In affected men, semen volume is decreased an average of 30%, with a smaller subgroup of patients also experiencing a decrease of sperm motility of 6 to 12%. Sperm shape and function are unaffected and the impact on male fertility is unknown. These negative effects reverse by 3–4 months after discontinuation of the drug. In a study of 6,729 men with benign prostatic hyperplasia (BPH, a condition where the prostate grows unassociated with cancer), 9% had erectile dysfunction (compared to 5.7% treated with a placebo), 3.3% experienced decreased sex drive (vs 1.6% of placebo), and 1.9% had enlarged breasts (vs 1% of placebo). These effects were noted to resolve over time, with many fewer men reporting any adverse effects by the end of the 4-year study. The rate of discontinuation of the drug due to adverse effects was less than 5%. A subset of men affected by sexual and mood side effects report persistent loss of libido, depression, and erectile dysfunction for several years after discontinuing treatment.

== Gene == The human CUX1 gene is large, encompassing more than 440,000 base pairs with two alternative first exons and an additional 23 exons. The last exon has a weak polyadenylation site allowing RNA polymerase II often to continue transcribing until it reaches an additional 10 exons. Splicing of this longer transcript from exon 14 to exon 25 generates a mature mRNA that codes for a protein that was called CASP (Cut alternatively spliced product). CASP localizes to the Golgi and does not seem to impact at all on CUX1 function. However, because of the complex structure of the gene, most oligos in microarrays were derived from the most 3' exons that are unique to CASP. Thus, until the advent of RNA sequencing CUX1 expression data has been essentially limited to immunohistochemical analyses. Similarly, many guide RNAs in CRISPR-Cas screening studies target the CASP-specific exons and do not affect CUX1.

=== Health care === In 2019, Pritzker approved a tax on private insurance to help fund the state's Medicaid program. In August of that year, he signed legislation to eliminate the state's backlog of Medicaid applications, which as of March 15, 2019, included 112,000 that remained unprocessed past the federal 45-day limit. According to data from the Illinois Department of Human Services, the backlog was eliminated as of June 2020. In August 2023, under provisions of Illinois House Bill 2189 (the Access to Afford Insulin Act), Pritzker signed legislation capping insurance holders' out-of-pocket price of insulin at $35 for a 30-day supply. In July 2024, Pritzker signed bills allowing Illinois to spend $10 million to purchase medical debt from creditors, known as the Medical Debt Relief Pilot Program, under the Illinois Department of Healthcare and Family Services. The program was created to eliminate nearly $1 billion in medical debt for 340,000 low-income state residents. In February 2025, Pritzker announced that approximately 270,000 Illinoisans' medical debt, totaling $345 million, had been erased under the program. On April 22, 2025, United States Secretary of Health and Human Services Robert F. Kennedy Jr. announced a plan to use government data to help determine the causes of autism. In response, Pritzker signed an executive order that made Illinois the first state to block the federal government from collecting personal health data related to autism. In 2025, Pritzker signed Illinois House Bill 1697, the Prescription Drug Affordability Act.

Oxaloacetate to malate, using NADH + H+ Oxaloacetate + NADH/H+ → Malate + NAD+ Fumarate to succinate, catalyzed by an oxidoreductase, Fumarate reductase Fumarate + FADH2 ⇌ Succinate + FAD Succinate to succinyl-CoA, an ATP-dependent step Succinate + ATP + CoA → Succinyl-CoA + ADP + Pi Succinyl-CoA to alpha-ketoglutarate, using one molecule of CO2 Succinyl-CoA + CO2 + Fd(red) → alpha-ketoglutarate + Fd(ox) Alpha-ketoglutarate to isocitrate, using NADPH + H+ and another molecule of CO2 Alpha-ketoglutarate + CO2 + NAD(P)H/H+ → Isocitrate + NAD(P)+ Citrate converted into oxaloacetate and acetyl-CoA, this is an ATP dependent step and the key enzyme is the ATP citrate lyase Citrate + ATP + CoA → Oxaloacetate + Acetyl-CoA + ADP + Pi This pathway is cyclic due to the regeneration of the oxaloacetate. The bacteria Gammaproteobacteria and Riftia pachyptila switch from the Calvin-Benson cycle to the rTCA cycle in response to concentrations of H2S.

Sources: en.wikipedia.org

Frequently asked questions

In which form is semax typically supplied?

Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.

Does semax occur naturally?

No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.

Why is it grouped with nootropics?

The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.

Semax 冻干粉可以常温保存吗?

一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受,但会加快降解风险。

Network